Real-world Effectiveness and Usage of Voclosporin: Data from the Enlight-LN Registry (ACR Convergence 2025) - Sep 15, 2025 - Abstract #0661; Pres time: Oct 26, 2025; 10:30 AM - 12:30 PM; Location: Hall F1; In Person; P | "During clinical trials, voclosporin, in combination with mycophenolate mofetil (MMF) and low-dose glucocorticoids, led to significant reductions in proteinuria with stable estimated glomerular filtration rate (eGFR) with up to 3 years of exposure compared to MMF and glucocorticoids alone. Patients in the Enlight-LN registry reflect the larger LN population in the US, including high percentages of Black and Hispanic and/or Latino patients. The outcomes data from this initial analysis are consistent with the findings from the voclosporin clinical trials, with substantial reductions in proteinuria observed over the first few months of treatment, with no new safety signals. These real-world data support the recent updates to the ACR guidelines recommending use of triple immunosuppressive therapy first-line in patients with active LN."
Clinical • Real-world • Real-world effectiveness • Real-world evidence • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Rheumatology
|
|
Leanna Wise1; Laura Geraldino-Pardilla2; Niloofar Nobakht3; Mohammad Kamgar3; Amber Rosales4; Barbara McIntosh4; Ron Flauto4
|